Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.24
- Piotroski Score 4.00
- Grade Sector Perform
- Symbol (PHR)
- Company Phreesia, Inc.
- Price $19.04
- Changes Percentage (2.81%)
- Change $0.52
- Day Low $18.20
- Day High $19.13
- Year High $29.16
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 12/09/2024
- Fiscal Year End N/A
- Average Stock Price Target $30.00
- High Stock Price Target $70.00
- Low Stock Price Target $23.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.16
- Trailing P/E Ratio -9.03
- Forward P/E Ratio -9.03
- P/E Growth -9.03
- Net Income $-136,885,000
Income Statement
Quarterly
Annual
Latest News of PHR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Humphrey Bogart, Lauren Bacall's son says young people 'not aware of the past,' don't know his famous parents
William J. Mann's book "Bogie & Bacall: The Surprising True Story of Hollywood's Greatest Love Affair" explores the iconic Hollywood couple. Stephen Bogart, son of Humphrey Bogart and Lauren Bacall, a...
By Fox News | 2 days ago -
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.
Stocks of major drug makers and biotech companies plummeted as Donald Trump expressed interest in appointing vaccine skeptic Robert F. Kennedy Jr. as head of the U.S. Department of Health and Human Se...
By Forbes | 6 days ago -
AbbVie's stock plummets over 12% after schizophrenia drug flops in Phase II trials
AbbVie's stock plummeted by 12% after its anti-psychotic drug, emraclidine, failed to meet primary endpoints in Phase II trials for schizophrenia treatment....
By Yahoo! Finance | 1 week ago
